Key Drivers
- Profitability Rebound
- Strong Liquidity
- Rising Leverage
AIAI Summary
View TFX as a focused medtech execution story—not a simple value rebound—with upside contingent on management using OEM-sale proceeds to deleverage and sustaining Vascular/Surgical growth while fixing Interventional; remain cautious until margin recovery and organic growth validate the reset.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Profitability Rebound
- •Strong Liquidity
- •Rising Leverage
TFX's latest quarter shows a strong earnings and cash-flow rebound, but elevated debt and intangible assets keep balance-sheet risk high.
Price Behavior
Key Price Behavior Insights:
- •Persistent selloff
- •Oversold momentum
- •Critical support
TFX remains bearish after a 12% drop over the last month, with deeply oversold momentum allowing for a rebound but requiring a hold above $124.50 and reclaim of $130–$132 to improve the outlook.
Sharp 12% decline from $142.05 to $124.52 over the last month
Sentiment & News
Key News Insights:
- •OEM sale
- •Debt reduction
- •Execution risk
Teleflex's OEM sale, debt reduction, and Vascular/Surgical growth support EPS upside, though Interventional execution and margin pressure remain key risks.
The portfolio transition could strengthen valuation and financial flexibility, but sustained upside depends on improved Interventional performance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings